A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT05171647)

🧪 Interventions in This Study

• Mosunetuzumab (DRUG)
• Polatuzumab vedotin (DRUG)
• Tocilizumab (DRUG)
• Rituximab (DRUG)
• Gemcitabine (DRUG)
• Oxaliplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

• City of Hope Cancer Center — Duarte, California
• St. Luke's Hospital — Chesterfield, Missouri
• Ascension Seton Infusion Center — Austin, Texas
• MD Anderson Cancer Center — Houston, Texas
• Hospital Aleman — Buenos Aires,
• Instituto Alexander Fleming — Buenos Aires,
• FUNDALEU — Buenos Aires,
• Hospital Italiano de Buenos Aires — Ciudad Autonoma Buenos Aires,
• Hospital Erasto Gaertner — Curitiba, Paraná
• Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul
• Hospital das Clínicas FMRP-USP — Ribeirão Preto, São Paulo
• Hospital Sao Jose — São Paulo, São Paulo
• D'or Instituto de Pesquisa e Educação — São Paulo,
• Hamilton Health Sciences - Juravinski Cancer Centre — Hamilton, Ontario
• Princess Margaret Hospital — Toronto, Ontario
• Chum Hopital Notre Dame — Montreal, Quebec
• Sichuan Cancer Hospital — Chengdu,
• Fujian Medical University Union Hospital — Fuzhou,
• Cancer Center, Sun Yat-sen University of Medical Sciences — Guangzhou,
• Tianjin Cancer Hospital — Tianjin,
• Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech — Wuhan,
• Henan Cancer Hospital — Zhengzhou,
• Soroka Medical Center — Beersheba,
• Ichilov Sourasky Medical Center — Tel Aviv,
• Kyushu University Hospital — Fukuoka,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Hodgkin Lymphoma

• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma — Tucson, Arizona
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies — Mobile, Alabama
• AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma — St Louis, Missouri
• Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma — Chicago, Illinois
• Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy — St Louis, Missouri

Explore by condition: All Non-Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.